Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United States of America
+1 (0)21 237 601 34Joint Bookrunner
Kempen & Co is pleased to announce that it acted as Joint Bookrunner in Q-linea’s SEK 301m Capital Increase
Q-linea is a diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. The company has signed a global partnership (excl. Sweden) with Thermo Fisher for the commercialisation of ASTar®. ASTar® recently achieved CE-IVD approval allowing Q-linea and Thermo Fisher to start commercialisation in Europe. In addition, the Q-linea recently initiated a 510(k) US clinical study for ASTar® with the goal of submitting a 510(k) application to the FDA during 2021.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: